Abingworth Llp Stake in Cymabay (CBAY) Decreased as Shares Rose

May 3, 2018 - By Maria Fierro

Abingworth Llp’s holdings in Cymabay (CBAY) is reduced by 25.65% based on its latest 2017Q4 regulatory filing with the SEC. 395,645 shares were sold by Abingworth Llp as the company’s stock rose 28.89% while stock markets declined. The major pharmaceuticals company at the end of 2017Q4 was priced at $10.55M. It’s down from 1.54M at the end of the previous reported quarter. Now it had 1.15 million shares held by the institutional investor . For a total of shares it increased its holding in by shares in the quarter, and has risen its stake in .

CymaBay Therapeutics, Inc. (NASDAQ:CBAY)’s earnings report is anticipated on May, 10., Zacks reports. This year’s earnings per share analyst estimate is anticipated to be $-0.14. That is 30.00 % up compareed to $-0.2 earnings per share for last year. 27.27 % negative EPS growth is what Wall Street’s forecasts after $-0.11 reported EPS previous quarter.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Ratings Coverage

A total of 8 analysts rate CymaBay Therapeutics (NASDAQ:CBAY) as follows: 8 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. The firm has $27.0 highest and $15.0 lowest target. The avg target $18.71 is 56.05% above the last ($11.99) price. (NASDAQ:CBAY) has 15 ratings reports on May 3, 2018 according to StockzIntelligence. In Tuesday, November 28 report Leerink Swann maintained it with “Buy” rating and $16.0 target. The stock rating was maintained by Piper Jaffray with “Buy” on Wednesday, January 31. On Friday, March 16 the stock has “Buy” rating by SunTrust. On Wednesday, January 24 the firm earned “Buy” rating by H.C. Wainwright. On Wednesday, March 28 the stock has “Buy” rating by H.C. Wainwright. On Monday, April 16 the firm earned “Buy” rating by Roth Capital. The stock rating was maintained by Oppenheimer with “Buy” on Wednesday, March 21. In Thursday, March 15 report Piper Jaffray maintained the stock with “Buy” rating. On Wednesday, March 28 the firm earned “Buy” rating by Leerink Swann. On Wednesday, April 11 the firm has “Buy” rating by Leerink Swann given.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: